Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Orders Firms To Submit Data For 25 Pre-Amendment Device Types

This article was originally published in The Gray Sheet

Executive Summary

FDA is requiring makers of 25 types of medical devices to submit safety and effectiveness information so the agency can decide whether to down-classify the products or require pre-market approval submissions

You may also be interested in...



Dueling Journal Commentaries Revisit FDA Approval of Abiomed's Impella

The pieces in JAMA Cardiology consider the merits of FDA's "515 Program Initiative" to classify preamendment devices and its application to a minimally invasive ventricular assist device.

Oxygenation Circuit Devices Find A Class II Home With FDA

The agency issued a final order reclassifying and renaming membrane lung devices to acknowledge their role as one component of a larger extracorporeal membrane oxygenation (ECMO) system. The decision follows 2013 and 2014 advisory panel recommendations.

FDA Calling For More PMAs Than 510(k)s In Final Set Of Preamendment Devices

“The Gray Sheet” reviewed CDRH’s proposed orders and final classification decisions on preamendment devices targeted by the 515 initiative. As of Aug. 5, FDA has proposed or finalized 14 PMAs, and proposed or finalized 10 products to be downclassified to class II with special controls.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel